TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04453917

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Collection of blood and urine
Description: Collection of blood (47 mL) and urine (5 mL) at PML diagnosis and 1, 3 and 6 months after, for analysis of immune checkpoint molecules expression, detection of antiviral immune responses and virological analyses.
Study: NCT05798325

Intervention type: OTHER
Group type: OTHER
Intervention: SF-MPQ
Description: The main component of the SF-MPQ consists of 15 descriptors (11 sensories; 4 affective) which are rated on an intensity scale as 0 = none, 1 = mild, 2 = moderate or 3 = severe.
Study: NCT04453917

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Spinal tap
Description: Spinal tap for monitoring of JC viral load at PML diagnosis and 1, 3 and 6 months after, and collection of CSF (2 mL) for virological analyses.
Study: NCT05798325

Intervention type: OTHER
Group type: OTHER
Intervention: FSS
Description: The Fatigue Severity Scale is used to assess the severity of fatigue and its impact on daily living. The patient responds on a Likert-type scale ranging from 1 to 7.

Intervention type: OTHER
Group type: OTHER
Intervention: IPAQ
Description: This questionnaire assesses overall physical activity and the level of sedentary lifestyle during the last seven days.

Intervention type: OTHER
Group type: OTHER
Intervention: Rang of motion
Description: The EasyAngle® is a digital goniometer improving long established goniometric functionality with rotation, inclination, and scoliosis measurement capabilities.

Intervention type: DEVICE
Group type: OTHER
Intervention: Goniometry
Description: The Links sensor system is a measuring device and consists of the Links Pods and the Links Hub. The Links pods contain an accelerometer, gyroscope and magnetometer to measure position relative to a global reference frame.

Intervention type: OTHER
Group type: OTHER
Intervention: Video captured monitoring
Description: Once every four weeks, while wearing the Yumen electronic goniometers (Links Sensor System), the patients will be asked to record on video three tasks related to:~1. Upper limbs: hands to head~2. Lower limbs: Sit to stand with or without the help of a person~3. Self-defined important task: A task of the patient's choice, from a list of tasks, representative of his/her motor difficulties or hindrance to autonomy.

Intervention type: DEVICE
Group type: OTHER
Intervention: Activity monitoring
Description: Wearable devices (connected watch) will collect health-related data on a 24/7 basis remotely as patients go through their daily routines at home and work.
Study: NCT06538376

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Portable Dynamic Digital Radiography (DDR)
Description: (DDR imaging has already been described in the arm/group description). Each patient in the study will receive at least one set of DDR images, which consists of one 7-second scan in which the patient breaths normally, and a second 7-second scan in which the patient holds their breath (or for ventilated patients, an inspiratory pause is placed by the care team).~If the patient's conditions warrant it, up to two sets of follow-up scans may be acquired. For instance, in a patient with diaphragmatic dysfunction, imaging may be completed pre- and post- diaphragmatic plication.
Study: NCT06129279

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EFT group
Description: Preliminary tests will be carried out and then the 1st EFT session will be held.~After 30 days, the first final tests will be performed and then the second EFT session will be held.~After 30 days, only the 2nd final tests will be performed.
Study: NCT05234047

Intervention type: PROCEDURE
Intervention: MDCT (multidetector computed tomography)
Description: MDCT will be performed at inclusion and after 2 years

Intervention type: PROCEDURE
Intervention: Dual-energy X-ray absorptiometry
Description: DXA will be performed at inclusion, 1 and 2 years after inclusion
Study: NCT05688800

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional therapy
Description: Participants in control group will receive conventional physical therapy treatment including Conventional TENS high frequency (90-130hz) low intensity according to the patient sensation for 30-45 min(Gozani, 2019) , continuous ultrasound with frequency 1 MHz and intensity 0.8 W/cm 2 will be applied by slow circular perpendicular movements with slightly deep pressure. Application time was 5 minutes at each side of the level of C7_T4 along the medial borders of the scapulae width, infra-red radiation will be four 15 minutes and directed perpendicular to the inter-scapular area, centered at the level of C7_T4 long and between the 2 medial borders of the scapulae width . Also combined stretching and strengthening exercise will be added due to its greater pain-relieving effect

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental group 1 : pressure release technique
Description: Participants who are assigned to this group will receive conventionalphysical therapy treatment in addition to pressure release technique. the participant will be positioned either sitting or prone position according to his preferred position, the researcher will apply the pressure release procedure by a pressure below the PPT dependent onsoft tissue release. When the researcher detected a reduction in soft tissue resistance, the amount of compression will be increased. The pressure should -33- be nonpainful, applied at slow rate, and will maintained until release of tissue barrier. Further pressure was increased to reach a new barrier. The pressure will last 60 seconds. With the thumb or the second and third fingers, the non-painful manual therapy approach was applied to the active MTrPs of therhomboid muscle

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental group 2: thoracic spine manipulation
Description: Thoracic spine manipulation will be performed as screw thrust manipulation technique; the vertebral transverse processes will beforced from posterior to anterior direction. The direction of the manipulation should be identified by applying springing test to the adjacent spinous process to determine the painful and stiff segment. Patient will be prone and researcher hand placement will be positioned as the following one pisiform on the right facet of the above, and the other pisiform on the left facet of the below vertebrae.A slack will be taken up. The thrust applied directly toward the patient once
Study: NCT05552183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral dose of 200 mg pacritinib twice daily (BID)
Description: Subjects will receive 200 mg BID pacritinib for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral dose of 200 mg pacritinib twice daily (BID)
Description: Subjects will receive 200 mg BID pacritinib for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral dose of 200 mg pacritinib twice daily (BID)
Description: Subjects will receive 200 mg BID pacritinib for 14 days.
Study: NCT05042128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LSTA1
Description: LSTA1 is a novel cyclic tumour-penetrating peptide iRGD (internalizing Arginylglycylaspartic acid) which may overcome poor drug delivery by activation of a complex trans-tissue transport pathway, providing an opportunity to overcome this mechanism of resistance in PDAC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LSTA1
Description: LSTA1 is a novel cyclic tumour-penetrating peptide iRGD (internalizing Arginylglycylaspartic acid) which may overcome poor drug delivery by activation of a complex trans-tissue transport pathway, providing an opportunity to overcome this mechanism of resistance in PDAC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Injection
Description: Chemotherapy drug provided as solution to be administered via IV infusion.
Study: NCT06474078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Description: Dosage/Frequency: 5mg - 10mg, oral, twice daily
Study: NCT05781074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: a PD-1 immune checkpoint inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib capsules

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoablation
Description: Cryoablation is performed under US or CT guidance per Investigator decision
Study: NCT06004986

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dupilumab
Description: Administering Dupilumab 300 mg at different dosing intervals.
Study: NCT05042128

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine Injection
Description: Chemotherapy drug provided as solution to be administered via IV infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine Injection
Description: Chemotherapy drug provided as solution to be administered via IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Injection
Description: Chemotherapy drug provided as solution to be administered via IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Chemotherapy drug provided as solution to be administered via IV infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nab paclitaxel
Description: Chemotherapy drug provided as solution to be administered via IV infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nab paclitaxel
Description: Chemotherapy drug provided as solution to be administered via IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Chemotherapy drug provided as solution to be administered via IV infusion.
Study: NCT05870566

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Corneal Crosslinking
Description: Riboflavin isotonic, 0,1 % Vitamin B2, with Dextran 20,0%, for epi-off procedure or Riboflavin isotonic 0,1% (Vitamin B2), 1,1% HPMC without Dextran for epi-off) 0.1% riboflavin-5-phosphate and 20% dextran T-500) will be applied to the cornea after epithelial debridement every 2 min for 10 minutes before irradiation and every 2 minutes during the course of a 10 minute exposure to 365 nm UV-A with an irradiance rate of 9 mW/cm2. This dose, mode and scheme of the intervention follows the internationally recognized accelerated CXL protocol (Elbaz et al. 2014). The data existing shows equivalent outcome regarding efficacy and safety compared to the standard protocol. To avoid any damage to the limbal stem cells, the limbus will not be irradiated during the procedure, as a CXL device (with maximal diameter of 11 mm) will be used. Furthermore, the limbal area will additionally be protected by a custom-cut LSC protection shield. (Protocol V04_0 Page 45-46)
Study: NCT04690946

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: 14-18 sessions of CBT

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Emotion-Focused Therapy
Description: 14-18 sessions of EFT
Study: NCT06650657

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: touchpoint method
Description: Touchpoint is a quality approach that can be applied to increase the sense of personal connection with the instructor, ensure that students are making satisfactory progress, increase instructor-student and student-instructor interactions, and increase student satisfaction, unlike traditional learning models.
Study: NCT06650891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quercetin
Description: oral quercetin prior to surgery

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsule identical looking to quercetin
Study: NCT06652204

Intervention type: OTHER
Intervention: questionnaire
Description: Caregivers must reply to the French version of the QASCI questionnaire, the ZBI (Zarit Burden Interview) questionnaire, HADS (Hospital Anxiety and Depression Scale), and WHOQOL-Bref (World Health Organization Quality of Life Instrument - Short Form). After 15 days, they wil reply to the French version of the QASCI questionnaire (to asse the reliability).
Study: NCT06653231

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: local delivery of Curcumin gel
Description: The test site will be completely undiluted curcumin gel through a 2 mL disposable syringe was placed in the test site and isolated with cotton rolls (not to contaminate the medication with saliva) Patients were recalled after a week for refrained from using any other oral hygiene measures in the observation period, recalled after a month for follow-up.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: local delivery of Curcumin gel
Description: The test site will be completely undiluted curcumin gel through a 2 mL disposable syringe was placed in the test site and isolated with cotton rolls (not to contaminate the medication with saliva) Patients were recalled after a week for refrained from using any other oral hygiene measures in the observation period, recalled after a month for follow-up.
Study: NCT04453917

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Brain MRI
Description: Brain MRI at at PML diagnosis and 3 and 6 months after

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neurological evaluation
Description: Neurological evaluation at PML diagnosis and 1, 3 and 6 months after
Study: NCT01395940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KLH-2109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KLH-2109
Study: NCT05795894

Intervention type: BEHAVIORAL
Intervention: STAI-Y
Description: Situational Anxiety and Trait Anxiety Inventory

Intervention type: BEHAVIORAL
Intervention: BDI scale
Description: • Beck Depression Inventory scale

Intervention type: BEHAVIORAL
Intervention: M.I.N.I.Kid
Description: Suicidal risk module of the Mini-International Neuropsychiatric Interview child/adolescent version

Intervention type: BEHAVIORAL
Intervention: PCL-5
Description: Post-traumatic Check List Scale
Study: NCT04887922

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIR Spirobank G
Description: FDA-approved, Bluetooth digital spirometer

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIR Spirobank G
Description: FDA-approved, Bluetooth digital spirometer

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ZEPHYRx®
Description: ZEPHYRx® has developed a 1) digital Bluetooth-enabled IS that allows for the continuous and objective remote monitoring of patient compliance with pre- and postoperative IS via a smartphone app and online provider dashboard.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ZEPHYRx®
Description: ZEPHYRx® has developed a 1) digital Bluetooth-enabled IS that allows for the continuous and objective remote monitoring of patient compliance with pre- and postoperative IS via a smartphone app and online provider dashboard.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional spirometer
Description: Will be provided to participants

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional spirometer
Description: Will be provided to participants
Study: NCT06004986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Administering Dupilumab 300 mg at different dosing intervals.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Administering Dupilumab 300 mg at different dosing intervals.
Study: NCT05265208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine will given at 1250mg/m², 2 times a day with an interval of about 12 hours between two intakes, 2 weeks on, 1 week off, for 4 pre-surgery cycles.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Selective Internal Radiotherapy (SIRT)
Description: During the first week of cycle 2 of capecitabine, patients will receive SIRT using Yttrium-90 glass microspheres. Treatment with Yttrium-90 glass microspheres requires two steps, one or two weeks apart. Both stages are performed under local anesthesia after a short hospitalization : the treatment simulation and therapeutic angiography.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery will be performed according to local practice.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgery
Description: Surgery will be performed according to local practice.
Study: NCT06271798

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Life style modification advice
Description: The lifestyle modification advice involves several key elements: reducing daily standing periods, avoiding excessive flexion of the knee joint during sitting, weight reduction, addressing cardio-respiratory conditions, incorporating venotonic agents, and utilizing below-knee elastic compression devices. These measures collectively aim to mitigate the development and progression of varicose veins, potentially preventing complications such as deep venous thrombosis and improving overall circulatory health.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Life style modification advice
Description: The lifestyle modification advice involves several key elements: reducing daily standing periods, avoiding excessive flexion of the knee joint during sitting, weight reduction, addressing cardio-respiratory conditions, incorporating venotonic agents, and utilizing below-knee elastic compression devices. These measures collectively aim to mitigate the development and progression of varicose veins, potentially preventing complications such as deep venous thrombosis and improving overall circulatory health.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistive exercise
Description: Participants in group A will perform resistive exercise. The patients will be instructed to do seated toe raises exercise or standing toe raise exercise. The exercise will be performed for 30 minutes, three times per week for six weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercises
Description: Participants in group B will perform aerobic exercise. Each session will begin with 10 min of low-intensity treadmill walking for a warm-up. The subsequent aerobic component will involve incline treadmill walking for 20 min at a perceived exertion of 6-7 (i.e., somewhat hard) on Borg's 3-10 scale followed by 10 min of low-intensity treadmill walking for cool down. The exercise will be performed for 30 minutes, three times per week for six weeks.
Study: NCT05137431

Intervention type: OTHER
Intervention: HFNO and NIV
Description: Patients meeting the inclusion criteria will be treated alternately with 2 hours of HFNO and 1 hour of NIV (HFNO-NIV for the same patient in turn). In 24 hours, there will be 16 hours of HFNO, 8 hours of NIV.~Parameters to record~* Respiratory parameters (respiratory rate)~* SpO2~* Ventilator settings~* Patient's tolerance (VAS; between 0-100)~* Arterial blood gas (HFNO and NIV at 1 hour)~* Clinical parameters (D dimer, CRP, ROX index)~Intubation criteria~* Loss of consciousness~* Agitation~* Persistent hypotension~* Need for fluid resuscitation~* Need for vasopressor~* Respiration rate ≥40/min~* SpO2 \<92~* pH\<7.30

Intervention type: OTHER
Intervention: HFNO and NIV
Description: Patients meeting the inclusion criteria will be treated alternately with 2 hours of HFNO and 1 hour of NIV (HFNO-NIV for the same patient in turn). In 24 hours, there will be 16 hours of HFNO, 8 hours of NIV.~Parameters to record~* Respiratory parameters (respiratory rate)~* SpO2~* Ventilator settings~* Patient's tolerance (VAS; between 0-100)~* Arterial blood gas (HFNO and NIV at 1 hour)~* Clinical parameters (D dimer, CRP, ROX index)~Intubation criteria~* Loss of consciousness~* Agitation~* Persistent hypotension~* Need for fluid resuscitation~* Need for vasopressor~* Respiration rate ≥40/min~* SpO2 \<92~* pH\<7.30
Study: NCT06650176

Intervention type: BEHAVIORAL
Intervention: Lifestyle Management
Description: The Metrikamind intervention features a unique digital ecosystem designed to manage mental health specifically in workplace contexts, with a focus on aiding recovery and facilitating the return to work for employees on sick leave. This innovative tool employs bifactor models to enhance the accuracy of self-reported data, effectively countering potential faking behaviors. Through continuous, real-time data collection on a user-friendly platform, Metrikamind tracks and assesses various mental health conditions, including stress, anxiety, and depression. The intervention\&amp;#39;s advanced analytics enable personalized feedback and targeted interventions, improving the detection, management, and ultimately, the mitigation of mental health issues. By focusing on individuals currently unable to work due to mental health challenges, Metrikamind aims to support their recovery and accelerate their readiness to return to work, thus addressing both immediate and long-term recovery trajectories.
Study: NCT05377541

Intervention type: PROCEDURE
Intervention: Surgical treatment of femur fracture
Description: Definitive surgical treatment of femur fracture.

Intervention type: PROCEDURE
Intervention: Surgical treatment of femur fracture
Description: Definitive surgical treatment of femur fracture.
Study: NCT04258826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3154207
Description: LY3154207 administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered orally.
Study: NCT05491382

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Uphill running
Description: Participants will run at 70% of their maximal oxygen consumption for 60 min at a 10 degree (17.6%) incline.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Uphill running
Description: Participants will run at 70% of their maximal oxygen consumption for 60 min at a 10 degree (17.6%) incline.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Uphill running
Description: Participants will run at 70% of their maximal oxygen consumption for 60 min at a 10 degree (17.6%) incline.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Flatland running
Description: Participants will run at 70% of their maximal oxygen consumption for 60 min at a 0 degree (0%) incline.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Flatland running
Description: Participants will run at 70% of their maximal oxygen consumption for 60 min at a 0 degree (0%) incline.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Flatland running
Description: Participants will run at 70% of their maximal oxygen consumption for 60 min at a 0 degree (0%) incline.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Downhill running
Description: Participants will run at 70% of their maximal oxygen consumption for 60 min at a -10 degree (-17.6%) decline.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Downhill running
Description: Participants will run at 70% of their maximal oxygen consumption for 60 min at a -10 degree (-17.6%) decline.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Downhill running
Description: Participants will run at 70% of their maximal oxygen consumption for 60 min at a -10 degree (-17.6%) decline.
Study: NCT06206525

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Initial insulin dosing using the calculator
Description: Participants will receive initial insulin doses by the calculator on hospital admission.